Mitral valve incompetence – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:49 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Mitral valve incompetence – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Title: Evaluation of optimal timing for heparin anticoagulation in patients undergoing transseptal heart procedures (TEER or left atrial appendage closure) https://clinicaltrials.eu/trial/study-on-optimizing-anticoagulation-timing-with-heparin-sodium-for-patients-undergoing-teer-or-left-atrial-appendage-closure-procedures/ Wed, 29 Apr 2026 15:02:20 +0000 https://clinicaltrials.eu/trial/study-on-optimizing-anticoagulation-timing-with-heparin-sodium-for-patients-undergoing-teer-or-left-atrial-appendage-closure-procedures/ This clinical trial focuses on finding the best timing for starting anticoagulation treatment in patients who undergo heart procedures requiring transseptal puncture (a technique that involves creating a small hole between the upper chambers of the heart). The study specifically looks at two types of procedures: Transcatheter Edge-to-Edge Repair (a minimally invasive procedure to repair a leaking heart valve) and Left Atrial Appendage Closure (a procedure to prevent blood clots in patients with irregular heartbeat).

The study uses two medications: Heparin, which is a blood-thinning medication given by injection, and physiological saline solution, which is a sterile salt water solution used during medical procedures. The main purpose is to determine when it is safest and most effective to start blood-thinning treatment in patients undergoing these heart procedures.

During the study, patients will receive either standard timing of blood-thinning medication or a different timing schedule. The effects will be monitored through various medical examinations, including imaging of the heart and brain, to ensure patient safety and evaluate the effectiveness of different timing approaches. The study will track any complications or adverse events that might occur during and after the procedures.

]]> Study on the Effects of Sacubitril and Valsartan in Patients with Heart Failure and Mitral Valve Regurgitation https://clinicaltrials.eu/trial/study-on-the-effects-of-sacubitril-and-valsartan-in-patients-with-heart-failure-and-mitral-valve-regurgitation/ Wed, 29 Apr 2026 14:26:33 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-sacubitril-and-valsartan-in-patients-with-heart-failure-and-mitral-valve-regurgitation/ This clinical trial is focused on studying the effects of a medication called Entresto, which contains the active substances valsartan and sacubitril, on patients with a specific type of heart condition known as Heart Failure with Preserved Ejection Fraction (HFpEF) and a related issue called Secondary Mitral Valve Regurgitation. Heart failure with preserved ejection fraction is a condition where the heart’s pumping ability is normal, but it has trouble relaxing and filling with blood. Secondary mitral valve regurgitation occurs when the heart’s mitral valve doesn’t close tightly, allowing blood to flow backward in the heart.

The purpose of this study is to assess how Entresto affects the heart’s function in these patients. Participants in the study will take Entresto in the form of film-coated tablets, which are taken orally. The study will last for about six months, during which time the effects of the medication on heart function will be monitored. Some participants may receive a placebo, which is a tablet that looks like the medication but does not contain the active substances.

Throughout the study, various tests will be conducted to evaluate heart function, including a combination of exercise testing and imaging techniques. These tests will help determine how the medication affects the heart’s ability to pump blood and the severity of the mitral valve regurgitation. The study will also look at changes in participants’ quality of life and other health indicators. The goal is to better understand how Entresto can help manage these heart conditions and improve patient outcomes.

]]>